[ET Net News Agency, 7 January 2022] BeiGene, Ltd. (06160) said the China National
Medical Products Administration (NMPA) has approved BeiGene's anti-PD-1 antibody
tislelizumab as a second- or third-line treatment for patients with locally advanced or
metastatic non-small cell lung cancer (NSCLC).
A supplemental biologics licence application for tislelizumab in this indication was
previously accepted for review by the China NMPA in March 2021. (RC)